The latest news for pharma industry insiders.
Priority review designation for Keytruda is based on promising results from the Phase II/III IND.227/KEYNOTE-483 trial, which demonstrated improved overall survival in patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Financial Burden of Private Healthcare Increased Over the Past Two Decades
Private healthcare is becoming more expensive for the nearly 180 million American families covered, according to the results of a study published in a JAMA Internal Medicine research letter.
Smart Bandages That Heal Wounds Faster and Talk to Your Doctor Are on the Way
Researchers are working on bandages that allow remote monitoring and deliver treatment with zaps of light or electricity.
Merck, known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
#RFID supports a more efficient and accurate medication-use process that can enhance #patientsafety, help prevent drug diversion, and give clinicians more time for patient care.https://ow.ly/Q5sY50RAizt Pharmaceutical Commerce MagazineFresenius Kabi #GS1Standards
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Racial, Social, and Economic Factors Drive Resilience During COVID-19 Pandemic, Study Finds
July 18th 2025The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.
Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production
July 16th 2025Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.